Adjunctive Brexpiprazole (OPC-34712) in Patients with Major Depressive Disorder and Sleep Disturbances: An Exploratory Study

被引：0
|
作者：
Krystal, Andrew [1 ]
Mittoux, Aurelia [2 ]
Meisels, Peter [2 ]
Baker, Ross [3 ]
机构：
[1] Duke Univ Hosp, Psychiat Brain Stimulat & Neurophysiol, Durham, NC USA
[2] H Lundbeck & Co AS, Clin, Valby, Denmark
[3] Otsuka Pharmaceut Dev & Commercializat Inc, CNS Global Med Affairs, Princeton, NJ USA
来源：
BIOLOGICAL PSYCHIATRY | 2015年 / 77卷 / 09期
关键词：
brexpiprazole;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
173
引用
收藏
页码：64S / 65S
页数：2
相关论文
共 50 条
  • [21] Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
    Thase, Michael E.
    Zhang, Peter
    Skuban, Aleksandar
    Hobart, Mary
    Weiss, Catherine
    Weiller, Emmanuelle
    Nelson, James C.
    [J]. CURRENT PSYCHIATRY REVIEWS, 2016, 12 (03) : 291 - 301
  • [22] Brexpiprazole (OPC-34712) vs aripiprazole in adults with acute schizophrenia: a multicenter, randomized, open-label, flexible-dose, exploratory study
    Citrome, L.
    Ota, A.
    Nagamizu, K.
    Perry, P.
    Weiller, E.
    Baker, R.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S516 - S517
  • [23] Effect of adjunctive brexpiprazole on functioning in three exploratory, open-label studies in major depressive disorder
    Baker, R.
    Matsushima, Y.
    Tsuneyoshi, K.
    Weiss, C.
    Skuban, A.
    Weiller, E.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S406 - S406
  • [24] Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
    Nelson, Craig
    Skuban, Aleksandar
    Zhang, Peter
    Weiller, Emmanuelle
    Weiss, Catherine
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 103 - 103
  • [25] Adjunctive brexpiprazole for treating major depressive disorder, meta-analysis
    Yoon, S.
    Han, C.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S462 - S463
  • [26] Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder
    Sussman, Matthew
    Yu, Jeffrey
    Kamat, Siddhesh A.
    Hartry, Ann
    Legacy, Susan
    Duffy, Ruth
    Aigbogun, Myrlene Sanon
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2017, 207 : 54 - 62
  • [27] Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress
    McIntyre, Roger S.
    Bubolic, Suzy
    Zhang, Zhen
    MacKenzie, Erin M.
    Therrien, Francois
    Miguelez, Maia
    Boucher, Matthieu
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2024, 44 (02) : 133 - 140
  • [28] Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy
    Krystal, Andrew D.
    Mittoux, Aurelia
    Lindsten, Annika
    Baker, Ross A.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 278 : 288 - 295
  • [29] A Real-life Study of Brexpiprazole as an Adjunctive Treatment for Major Depressive Disorder in Asian Patients in Singapore (BADA)
    Mok, Yee Ming
    Tan, Pei Lin Lynnette
    Bose, Rohini
    Herr, Keira Joann
    Ung, Ken Eng Khean
    [J]. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2024, 22 (03) : 531 - 536
  • [30] Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
    Fleischhacker, W. Wolfgang
    Hobart, Mary
    Ouyang, John
    Forbes, Andy
    Pfister, Stephanie
    McQuade, Robert D.
    Carson, William H.
    Sanchez, Raymond
    Nyilas, Margareta
    Weiller, Emmanuelle
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (01): : 11 - 21
12345